vs
AVANOS MEDICAL, INC.（AVNS）与南玻集团（CSGS）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是AVANOS MEDICAL, INC.的1.8倍（$323.1M vs $180.9M），南玻集团净利率更高（2.2% vs -0.7%，领先2.9%），南玻集团同比增速更快（2.0% vs 0.7%），南玻集团自由现金流更多（$55.8M vs $21.3M），过去两年南玻集团的营收复合增速更高（4.6% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
AVNS vs CSGS — 直观对比
营收规模更大
CSGS
是对方的1.8倍
$180.9M
营收增速更快
CSGS
高出1.3%
0.7%
净利率更高
CSGS
高出2.9%
-0.7%
自由现金流更多
CSGS
多$34.5M
$21.3M
两年增速更快
CSGS
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $323.1M |
| 净利润 | $-1.3M | $7.0M |
| 毛利率 | 47.5% | 50.0% |
| 营业利润率 | 1.4% | 9.0% |
| 净利率 | -0.7% | 2.2% |
| 营收同比 | 0.7% | 2.0% |
| 净利润同比 | 99.7% | -79.7% |
| 每股收益（稀释后） | $-0.02 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSCSGS
| Q4 25 | $180.9M | $323.1M | ||
| Q3 25 | $177.8M | $303.6M | ||
| Q2 25 | $175.0M | $297.1M | ||
| Q1 25 | $167.5M | $299.5M | ||
| Q4 24 | $179.6M | $316.7M | ||
| Q3 24 | $170.4M | $295.1M | ||
| Q2 24 | $171.7M | $290.3M | ||
| Q1 24 | $166.1M | $295.1M |
净利润AVNSCSGS
| Q4 25 | $-1.3M | $7.0M | ||
| Q3 25 | $-1.4M | $20.5M | ||
| Q2 25 | $-76.8M | $12.3M | ||
| Q1 25 | $6.6M | $16.1M | ||
| Q4 24 | $-397.3M | $34.5M | ||
| Q3 24 | $4.3M | $19.1M | ||
| Q2 24 | $1.8M | $13.8M | ||
| Q1 24 | $-900.0K | $19.5M |
毛利率AVNSCSGS
| Q4 25 | 47.5% | 50.0% | ||
| Q3 25 | 48.4% | 48.1% | ||
| Q2 25 | 52.6% | 49.5% | ||
| Q1 25 | 53.6% | 48.4% | ||
| Q4 24 | 54.6% | 51.3% | ||
| Q3 24 | 54.5% | 49.4% | ||
| Q2 24 | 55.7% | 47.3% | ||
| Q1 24 | 57.1% | 46.5% |
营业利润率AVNSCSGS
| Q4 25 | 1.4% | 9.0% | ||
| Q3 25 | 0.1% | 10.0% | ||
| Q2 25 | -42.6% | 10.0% | ||
| Q1 25 | 6.1% | 9.8% | ||
| Q4 24 | -233.0% | 13.4% | ||
| Q3 24 | 7.0% | 10.8% | ||
| Q2 24 | 3.7% | 8.8% | ||
| Q1 24 | 2.4% | 10.8% |
净利率AVNSCSGS
| Q4 25 | -0.7% | 2.2% | ||
| Q3 25 | -0.8% | 6.7% | ||
| Q2 25 | -43.9% | 4.1% | ||
| Q1 25 | 3.9% | 5.4% | ||
| Q4 24 | -221.2% | 10.9% | ||
| Q3 24 | 2.5% | 6.5% | ||
| Q2 24 | 1.0% | 4.8% | ||
| Q1 24 | -0.5% | 6.6% |
每股收益（稀释后）AVNSCSGS
| Q4 25 | $-0.02 | $0.24 | ||
| Q3 25 | $-0.03 | $0.73 | ||
| Q2 25 | $-1.66 | $0.44 | ||
| Q1 25 | $0.14 | $0.57 | ||
| Q4 24 | $-8.64 | $1.20 | ||
| Q3 24 | $0.09 | $0.67 | ||
| Q2 24 | $0.04 | $0.48 | ||
| Q1 24 | $-0.02 | $0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $180.0M |
| 总债务越低越好 | $90.3M | $539.5M |
| 股东权益账面价值 | $778.2M | $283.7M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.12× | 1.90× |
8季度趋势，按日历期对齐
现金及短期投资AVNSCSGS
| Q4 25 | $89.8M | $180.0M | ||
| Q3 25 | $70.5M | $158.4M | ||
| Q2 25 | $90.3M | $145.9M | ||
| Q1 25 | $97.0M | $136.0M | ||
| Q4 24 | $107.7M | $161.8M | ||
| Q3 24 | $89.0M | $118.4M | ||
| Q2 24 | $92.2M | $110.4M | ||
| Q1 24 | $75.8M | $120.8M |
总债务AVNSCSGS
| Q4 25 | $90.3M | $539.5M | ||
| Q3 25 | $93.4M | $538.6M | ||
| Q2 25 | $95.7M | $537.8M | ||
| Q1 25 | $98.0M | $537.6M | ||
| Q4 24 | $125.3M | $538.5M | ||
| Q3 24 | $152.6M | $539.5M | ||
| Q2 24 | $164.9M | $540.5M | ||
| Q1 24 | $167.2M | $541.5M |
股东权益AVNSCSGS
| Q4 25 | $778.2M | $283.7M | ||
| Q3 25 | $778.0M | $289.5M | ||
| Q2 25 | $776.3M | $290.7M | ||
| Q1 25 | $839.4M | $283.1M | ||
| Q4 24 | $828.5M | $282.6M | ||
| Q3 24 | $1.2B | $288.4M | ||
| Q2 24 | $1.2B | $273.3M | ||
| Q1 24 | $1.2B | $269.3M |
总资产AVNSCSGS
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.7B | $1.4B | ||
| Q2 24 | $1.7B | $1.4B | ||
| Q1 24 | $1.7B | $1.3B |
负债/权益比AVNSCSGS
| Q4 25 | 0.12× | 1.90× | ||
| Q3 25 | 0.12× | 1.86× | ||
| Q2 25 | 0.12× | 1.85× | ||
| Q1 25 | 0.12× | 1.90× | ||
| Q4 24 | 0.15× | 1.91× | ||
| Q3 24 | 0.12× | 1.87× | ||
| Q2 24 | 0.13× | 1.98× | ||
| Q1 24 | 0.14× | 2.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $59.2M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $55.8M |
| 自由现金流率自由现金流/营收 | 11.8% | 17.3% |
| 资本支出强度资本支出/营收 | 3.8% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 8.46× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $141.4M |
8季度趋势，按日历期对齐
经营现金流AVNSCSGS
| Q4 25 | $28.2M | $59.2M | ||
| Q3 25 | $14.0M | $47.9M | ||
| Q2 25 | $6.8M | $37.3M | ||
| Q1 25 | $25.7M | $11.5M | ||
| Q4 24 | $57.9M | $82.5M | ||
| Q3 24 | $23.0M | $39.5M | ||
| Q2 24 | $27.8M | $43.1M | ||
| Q1 24 | $-8.0M | $-29.4M |
自由现金流AVNSCSGS
| Q4 25 | $21.3M | $55.8M | ||
| Q3 25 | $7.0M | $43.9M | ||
| Q2 25 | $-4.2M | $34.6M | ||
| Q1 25 | $19.0M | $7.1M | ||
| Q4 24 | $53.1M | $76.6M | ||
| Q3 24 | $20.0M | $32.0M | ||
| Q2 24 | $21.9M | $38.8M | ||
| Q1 24 | $-12.1M | $-34.1M |
自由现金流率AVNSCSGS
| Q4 25 | 11.8% | 17.3% | ||
| Q3 25 | 3.9% | 14.5% | ||
| Q2 25 | -2.4% | 11.6% | ||
| Q1 25 | 11.3% | 2.4% | ||
| Q4 24 | 29.6% | 24.2% | ||
| Q3 24 | 11.7% | 10.8% | ||
| Q2 24 | 12.8% | 13.4% | ||
| Q1 24 | -7.3% | -11.6% |
资本支出强度AVNSCSGS
| Q4 25 | 3.8% | 1.1% | ||
| Q3 25 | 3.9% | 1.3% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 1.5% | ||
| Q4 24 | 2.7% | 1.9% | ||
| Q3 24 | 1.8% | 2.5% | ||
| Q2 24 | 3.4% | 1.5% | ||
| Q1 24 | 2.5% | 1.6% |
现金转化率AVNSCSGS
| Q4 25 | — | 8.46× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | 3.04× | ||
| Q1 25 | 3.89× | 0.71× | ||
| Q4 24 | — | 2.39× | ||
| Q3 24 | 5.35× | 2.07× | ||
| Q2 24 | 15.44× | 3.12× | ||
| Q1 24 | — | -1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
